Approximately 6% of the total population is ≥ 75 years old, but > 50% of CV deaths occur in this group of patients. This burden will only increase as patients are living longer, and men and women ≥ 80 years old account for a disproportionate number of deaths from CVD.2 Due to age related CV structure and function, and added age related changes in kidney, liver, brain, skeletal systems, etc. Our elderly are more vulnerable to the negative effects of both nonpharmacological and pharmacological treatments normally used in younger populations.3,4